Építés alatt – nem éles oldal
Belépés
Befejeződött4. fázis

Assessment of Safety , Clinical Efficacy With QLETLI in Non-infectious Uveitis (UV)

A legfontosabb adatok

Ki végzi
Bio-Thera Solutions
Hol
Kína7 helyszín, 1 országbanVálassz országot a helyszínekhez
Azonosító
Állapot
Befejeződött
Fázis
4. fázis
Résztvevők
60 fő vett részt
Kezdés
2021. dec. 27.
Befejezés
2025. aug. 5.
A vizsgálat típusa
Beavatkozással járó
A vizsgált kezelések
  • QLETLI
A regiszteradat frissítve
2026. október 13.

Ki vehet részt

Életkor
18 év – 70 év
Nem
Nők és férfiak
Egészséges önkéntesek
Nem vehetnek részt

A regiszter feltételei, szó szerint

Mind a 36 feltétel megnézéseKevesebb

Ki vehet részt

  • Patients voluntarily participated in the study and signed informed consent
  • Aged between 18 and 70 (including threshold), male or female
  • Diagnosis of non-infectious intermediate, posterior, or total uveitis in at least one eye
  • Received maintenance therapy (oral prednisone 10-60mg/day or equivalent glucocorticoid for ≧2 weeks before screening, and no dose adjustment from screening to baseline
  • At baseline, at least one eye was diagnosed with active uveitis, presenting as meeting at least one of the following criteria: active inflammatory chorioretinal and/or inflammatory retinal vasculopathy; Cell grade of anterior chamber ≧2+; Degree of vitreous turbid ≧2+
  • Negative serum pregnancy test results of women of childbearing age during screening visits

Ki nem vehet részt

  • Uncontrolled glaucoma, defined as intraocular pressure higher than 25 mmHg after drug treatment, or optic nerve damage
  • Peribulbar, intravitreal or subocular corticosteroid injections were given within 30 days prior to screening
  • Posterior capsulotomy was performed within 30 days prior to screening
  • Cataract surgery is expected within 90 days prior to screening or during the study period
  • An intravitreal injection of anti-VEGF therapy (e.g., raizumab, apecivir, or Combocept) within 90 days prior to baseline
  • Ozurdex implants (dexamethasone implants) were performed within 6 months prior to baseline
  • Treatment with intravitreal injection of methotrexate within 90 days prior to baseline
  • Had been treated with vitreous Retisert (glucocorticoid implant) or had complications with the implant during the 36 months prior to baseline; Removal of Retisert within 90 days prior to baseline or complications of removal
  • Prior treatment with anti-TUMOR necrosis factor TNF or other biological agents with potential therapeutic effect for uveitis (excluding intravitreal anti-VEGF drugs)
  • During the 30 days prior to baseline, the combined dose of other immunosuppressant therapy increased or did not meet any of the following conditions: methotrexate MTX≤25mg/ week; Cyclosporine ≤4 mg/kg/ day; Mycophenolate (or equivalent dose of mycophenolate) ≤2g/ day; Azathioprine ≤175 mg/ day; Tacrolimus oral ≤8 mg/ day
  • Received clinical trial drug intervention within 3 months prior to screening
  • Received any live vaccine within 3 months prior to receiving the first dose of the study drug, or planned to receive live vaccine during the study period
  • There are contraindications to dilatation drugs
  • Patients with the following eye conditions:
  • is confirmed or suspected infectious uveitis (including but not limited to the following causes of infectious uveitis, tuberculosis, cytomegalovirus, lyme disease, toxoplasmosis, human, T, Whipple's disease virus type 1 infection, herpes zoster virus and herpes simplex virus) or disguise syndrome (for example: eye trauma, lymphoma, malignant tumor, or surgery, etc.)
  • Demyelinating disease (including myelitis and optic neuritis) or a history of neurology suggesting symptoms of demyelinating disease (including but not limited to optic neuritis)
  • Refractive media opacity or pupil failure that significantly interferes with visual acuity detection, anterior segment and fundus assessment
  • Having any of the following general conditions:
  • Positive hepatitis C antibody during screening; Or HIV antibody positive; Or treponema pallidum antibody positive
  • Symptoms of severe, progressive or uncontrollable kidney, liver, blood, gastrointestinal, lung, cardiovascular, neurological or brain disease. The investigator felt that participating in the study placed patients at unacceptable risk
  • Patients with malignant tumors
  • Patients with moderate to severe heart failure (New York Heart Society Grades 3-4)
  • History of severe allergy or anaphylactoid reaction to monoclonal antibodies
  • With other fundus diseases (such as fertile or serious non fertile diabetic retinopathy or diabetic retinopathy with clinical significance of macular edema, retinal vein occlusion, macular degeneration, age, sex, blood vessel patterns change, the pathological myopia, retinal detachment, macular hole, toxoplasmosis, optic nerve disease, etc.)
  • Subjects meet any of the following criteria associated with latent or active tuberculosis (TB) infection:; . A history of active TB ≤ 3 years before screening (but can also be included if it is > 3 years and documented completion of adequate treatment); B. Signs or symptoms suggestive of active TB at the time of screening in the history and/or physical examination; C. Recent close contact with someone with active TB; D. If a TB infection T-cell test is positive at the time of screening, subjects will be excluded from the study if their first TB infection T-cell test is inconclusive. For suitable standards has been completed before screening latent TB treatment and no other risk factors, imaging findings, or support the latent or signs of active TB specific subjects, for positive or uncertain results may be the exception handling, researchers with the qualified physician judgment, tuberculosis (including extrapulmonary) risk, decision and discuss with bidders
  • Patients with simple anterior uveitis
  • Uveitis with macular edema as the only manifestation
  • Best corrected visual acuity of less than 20 letters in at least one eye at baseline
  • One-eyed patients deemed unsuitable for inclusion by the investigator
  • Patients judged unsuitable for inclusion by other investigators

Ennek a vizsgálatnak nincs helyszíne itt: Egyesült Államok.

Egy országban van helyszíne. Válassz országot, hogy lásd a helyszíneket.

A vizsgálatról

Mit akar kideríteni a vizsgálat

This is a multicenter, prospective, post-marketing clinical study with a total of 60 uveitis (UV) subjects planned to be enrolled.

A teljes eredeti leírásKevesebb

Screening period (-2~0 weeks) ,Treatment period (1-22 weeks), Follow-up period, At the same time, plasma concentration will be determined

A vizsgálat csoportja

  • ExperimentalA vizsgált kezelés

    80 mg was given subcutaneously at week 1, followed by 40 mg of Glorio (adamuzumab injection) every other week from week 1 to week 22 (12 doses).

    Kezelés: QLETLI

Adatok és források

Regiszteradat
Szerepel a ClinicalTrials.gov-on.
Hivatalos cím
A Multicenter, Prospective, Post-marketing Evaluation of QLETLI (Adalimumab Injection) Treatment Clinical Study on Efficacy and Safety of Non-infectious Uveitis (UV)
A regiszteradat frissítve
2026. október 13.